

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 July 2022 (21.07.2022)



(10) International Publication Number
WO 2022/152529 A1

(51) International Patent Classification:
A24B 15/167 (2020.01)

(21) International Application Number:
PCT/EP2021/087213

(22) International Filing Date:
22 December 2021 (22.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2100353.8 12 January 2021 (12.01.2021) GB

(71) Applicant: **VENTUS MEDICAL LIMITED** [GB/GB];
Unit 8, The Matchworks, Speke Road, Garston, Liverpool
Merseyside L19 2RF (GB).

(72) Inventors: **LAWSON, David**; Unit 8, The Matchworks,
Speke Road, Garston, Liverpool Merseyside L19 2RF (GB).

DIGNUM, Mark; Unit 8, The Matchworks, Speke Road,
Speke, Liverpool Merseyside L19 2RF (GB).

(74) Agent: **OPUS IP LIMITED**; New Mansion House,
173-191 Wellington Road South, Stockport, Greater Man-
chester SK1 3UA (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: AEROSOLIZABLE NICOTINE-CONTAINING FORMULATIONS




FIG. 3

(57) Abstract: Novel Nicotine-containing formulations for eCigarette and other electric/electronic nicotine delivery systems (ENDS) are disclosed. The formulations disclosed contain both nicotine at relatively much higher concentrations, typically at least 25% by weight of total formulation weight, w/w, and in many cases as much as 40-50% w/w, than is typical for conventional nicotine containing formulations, which only contain about 2-4% w/w nicotine. The formulations of the present invention additionally include a biologically and pharmaceutically acceptable mono- or di-carboxylic organic acid, such as benzoic acid, salicylic acid and most preferably lactic acid also at relatively high w/w concentrations. By including an acid in the formulation, one or more nicotine salts may be created and be extant within the formulations of the present invention, and this not only mitigates against the loss of nicotine to the atmosphere through natural volatility and evaporation, but also markedly increases the surface energy of the formulations thus created, meaning the globules of formulations deposited on a heating substrate are much more cohesive and much less likely to migrate through wetting

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

over the substrate.